Which of the following statements is true regarding the manipulation of cancer drugs using nanotechnology?

The manipulation of cancer drugs using nanotechnology allows for the development of targeted therapies, which significantly improves treatment outcomes. The ability to design nanotechnology-based drugs to trigger apoptosis specifically in cancer cells represents a breakthrough in oncology. Apoptosis is a process of programmed cell death that is often defective in cancer cells, making it crucial to restore this mechanism as a means of killing the cancerous cells effectively.

With nanotechnology, drugs can be engineered at a molecular level to deliver therapeutic agents directly to tumor cells while minimizing damage to surrounding healthy tissue. This specificity reduces side effects associated with traditional chemotherapy and increases the overall efficacy of cancer treatments. By honing in on the cancer cells and inducing apoptosis, these advanced drug formulations improve the precision of cancer treatment and the quality of life for patients.

In contrast, other statements do not align with the current capabilities of nanotechnology in cancer treatment. The assertion that these drugs cannot be made in-situ overlooks the fact that some nanomedicines are indeed devised to be produced locally within the body. Claiming they are less effective than traditional drugs is misleading, as many studies suggest that targeted nanotechnology formulations can outperform conventional drugs in specific scenarios. Lastly, the idea that nanotechnology-based treatments are designed for blanket treatment of all cells